bit.bio Raises $25 Million in Series D

The Cambridge human cell programming company secured the funding as demand for its human cell models reached record levels.

Updated on Nov. 4, 2026 in Biotech

bit.bio, a Cambridge-based human cell programming company, has raised $25 million in Series D funding. The round follows a $50 million Series C earlier in 2026 and includes backing from existing investor M&G Investments and Dr Jonathan Milner, founder and former CEO of Abcam.

Why it matters

Demand for human cell models is growing as AI-driven drug discovery accelerates and the field moves toward alternatives to animal testing. The funding will support portfolio expansion and wider customer access.

bit.bio's ioCells portfolio spans more than 50 human cell types, produced using its proprietary opti-ox platform, which enables defined cell types to be manufactured consistently and at scale. The company reports established manufacturing capacity, though the source does not provide production volume figures.

The players

bit.bio

A Cambridge-based human cell programming company whose ioCells portfolio provides defined human cell types for research and drug discovery.

M&G Investments

An existing investor in bit.bio that participated in the Series D round.

Dr Jonathan Milner

Founder and former CEO of Abcam, the antibody and life science reagents company, who backed the Series D round.

The details

bit.bio uses its opti-ox platform to produce defined human cell types consistently at scale. The company says its ioCells portfolio covers more than 50 cell types and that demand has reached record levels across its customer base.

Earlier in 2026: bit.bio completed a $50 million Series C round.
So far in 2026: Paid vial volumes increased 76 percent.
August 2026: Business Weekly flagged bit.bio's growth and scaling intentions in a special feature.
Mid-September 2026: bit.bio won the Life Science Innovation award at the Business Weekly Awards.
November 4, 2026: The $25 million Series D funding was announced.

The Tech Race

The shift toward human-derived cell models follows the broader move away from animal testing in drug development, a trend that has gained momentum as regulators and pharmaceutical developers look for more predictive preclinical tools. bit.bio's growth positions it among companies competing to supply that market at commercial scale.

Researchers and drug developers gain access to a wider range of human cell models as bit.bio expands its portfolio and customer base. Greater availability of these models could affect how new medicines are tested before reaching patients.

The takeaway

Growth in human cell models signals a practical shift in how biomedical research is conducted, with implications for both laboratory workflows and drug development timelines. Readers following life sciences investment can track whether demand gains translate into sustained commercial adoption.